Amgen Inc (AMGN) 155.75 $AMGN
Look for Shares of Amgen to Potentially Pullback after Yesterday's 2.26% Rise
Comtex SmarTrend(R) - 1 hr 38 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.86 to a high of $156.20. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $155.00 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 155.75 (+3.44)
After Yesterday's Rally of 2.26% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 1 hr 39 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.86 to a high of $156.20. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $155.00 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 155.75 (+3.44)
Amgen Announces Webcast of 2015 Third Quarter Financial Results
PR Newswire - Fri Oct 23, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 28, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 155.75 (+3.44)
Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:36PM CDT
Exelixis (EXEL) has started the process of a rolling submission of a new drug application to the FDA for Cometriq for the treatment of advanced kidney cancer.
AZN: 31.36 (+0.29), AMGN: 155.75 (+3.44), EXEL: 5.79 (+0.22)
eBay's (EBAY) 1st Earnings without PayPal: What's in Store? (revised)
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:03PM CDT
Our proven model shows that eBay is likely to beat earnings because it has the right combination of two key ingredients.
SKYW: 19.90 (+0.36), EBAY: 28.16 (+0.58), AMGN: 155.75 (+3.44), ANIK: 34.87 (+1.25)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Oct 23, 12:43PM CDT
All times are Eastern.
RAI: 48.89 (+0.01), F: 15.67 (+0.09), QSR.TO: 49.17 (+0.57), ANTX: 47.28 (+0.16), PFE: 34.05 (+0.72), XOM: 82.98 (+0.09), AMGN: 155.75 (+3.44), CMCSK: 62.35 (+0.28), MO: 61.05 (-0.35), AET: 105.89 (+2.53), SBUX: 62.61 (+1.12), ANTM: 140.95 (+1.54), QSR: 37.33 (+0.33), GT: 32.97 (+0.40), WBA: 89.96 (+1.33), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), CVS: 103.95 (-0.34), TWTR: 30.28 (+1.13), CMCSA: 61.98 (+0.28), AAPL: 119.08 (+3.58), BABA: 75.62 (+4.63)
Relypsa's Hyperkalemia Drug Veltassa Approved in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 12:43PM CDT
Relypsa (RLYP) announced that its Veltassa was approved in the U.S. for the treatment of hyperkalemia.
ZSPH: 65.45 (+1.53), AZN: 31.36 (+0.29), RLYP: 13.80 (+2.04), AMGN: 155.75 (+3.44)
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:12AM CDT
Spectrum (SPPI) announced that it has received a Complete Response Letter (CRL) from the FDA for Evomela.
AZN: 31.36 (+0.29), LGND: 89.30 (+2.20), AMGN: 155.75 (+3.44), SPPI: 5.33 (-1.31)
Foamix Starts Patient Enrollment in Phase II Study on FMX103
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:03AM CDT
Foamix (FOMX) announced the initiation of patient enrollment in a phase II study on FMX103 for the treatment of papulopustular rosacea.
AZN: 31.36 (+0.29), FOMX: 6.99 (+0.49), AMGN: 155.75 (+3.44), ANIK: 34.87 (+1.25)
Cat Allergy Pipeline Review, H2 2015 - 5 Companies & 2 Drug Profiles
M2 - Fri Oct 23, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sbgnrg/cat_allergy) has announced the addition of the "Cat Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cat Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cat Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Amgen Inc. - Biomay AG - Circassia Pharmaceuticals Plc - Laboratorios LETI S.L. Drug Profiles - AMG-157 - BM-36 For more information visit http://www.researchandmarkets.com/research/sb...at_allergy
AMGN: 155.75 (+3.44)
Global Anal Cancer Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Oct 23, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v4vqf/anal_cancer) has announced the addition of the "Anal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advaxis, Inc. - Amgen Inc. - Eli Lilly and Company - ISA Pharmaceuticals B.V. - MedImmune, LLC - Novartis AG - Sun Pharma Advanced Research Company Ltd. Drug Profiles - axalimogene filolisbac - Cell Therapy for HPV Associated Cancers - durvalumab tremelimumab - ISA-101 - paclitaxel albumin free - panitumumab - PDR-001 - prexasertib For more information visit http://www.researchandmarkets.com/research/5v...nal_cancer
ADXS: 10.77 (+0.47), AMGN: 155.75 (+3.44), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Battle Royale: Amgen Inc. vs. Biogen Inc.
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 23, 7:42AM CDT
Image source: Wikipedia.org . On the surface, Amgen and Biogen might not look like competitors. The two big biotechs don't go head-to-head with any of their major drugs. But there's one important way that Amgen and Biotech do battle against...
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44)
Amgen Receives CHMP Positive Opinion For IMLYGIC(TM) (Talimogene Laherparepvec)
PR Newswire - Fri Oct 23, 6:22AM CDT
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending that IMLYGIC(TM) (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. If approved by the European Commission, IMLYGIC would be the first in a class of novel agents known as oncolytic immunotherapies.
AMGN: 155.75 (+3.44)
Global Preventive Asthma Drugs Market 2015-2019
M2 - Fri Oct 23, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nsm45k/global_preventive) has announced the addition of the "Global Preventive Asthma Drugs Market 2015-2019" report to their offering. The global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019. The report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations. This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma: - Immunosuppressants - Leukotriene antagonists - Mast cell stabilizers - Corticosteroids - Combination of LABA/ ICS Key vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Other prominent vendors - Abbott - Amgen - AptarGroup - Biotest - Boehringer Ingelheim - Chiesi Farmaceutici - Cytos - Dainippon Sumitomo - Medicinova - Mylan - Novartis - Orchid Chemicals and Pharmaceuticals - Pfizer - Rottapharm Madaus - Skyepharma - Sosei - Sunovion - Teva Pharmaceutical - Theravance - Vectura For more information visit http://www.researchandmarkets.com/research/ns...preventive
MRK: 52.88 (+0.87), AMGN: 155.75 (+3.44), GSK: 42.11 (+0.67), ATR: 71.40 (+0.11), NVS: 92.98 (+0.55)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Stock Market News for October 22, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 9:10AM CDT
Benchmarks ended Wednesday’s volatile trading session in the red following declines in healthcare and energy shares
KO: 42.79 (-0.45), KMI: 29.23 (-0.52), VRX: 116.16 (+6.29), MDT: 73.69 (+0.62), PFE: 34.05 (+0.72), UNH: 115.92 (+2.11), AMGN: 155.75 (+3.44), XOM: 82.98 (+0.09), COP: 54.61 (+0.03), BMY: 65.16 (+1.98), BA: 146.70 (+0.39), YHOO: 33.17 (+1.50), GM: 35.95 (+0.53), CVX: 91.24 (-0.38), OXY: 73.71 (-0.63)
Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN.
ABT: 43.60 (+0.10), CMG: 649.72 (-0.90), HZNP: 17.06 (+3.94), AMGN: 155.75 (+3.44), BAC: 16.52 (+0.36)
The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
HD: 124.61 (+0.25), NKE: 130.53 (-1.88), AMGN: 155.75 (+3.44), MO: 61.05 (-0.35), AAPL: 119.08 (+3.58)
Go Back to the Future with These 5 Market Crushing Stocks
Eric Dutram - Zacks Investment Research - Wed Oct 21, 3:55PM CDT
If you ever have a time machine that can go back to 1985, you better buy these top performing stocks which have crushed the market over the past 30 years.
HD: 124.61 (+0.25), NKE: 130.53 (-1.88), AMGN: 155.75 (+3.44), MO: 61.05 (-0.35), AAPL: 119.08 (+3.58)
Look for Shares of Amgen to Potentially Pullback after Yesterday's 2.26% Rise
Comtex SmarTrend(R) - 1 hr 38 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.86 to a high of $156.20. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $155.00 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 155.75 (+3.44)
After Yesterday's Rally of 2.26% Shares Could Potentially Pullback
Comtex SmarTrend(R) - 1 hr 39 mins ago
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $151.86 to a high of $156.20. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $155.00 on volume of 3.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AMGN: 155.75 (+3.44)
Amgen Announces Webcast of 2015 Third Quarter Financial Results
PR Newswire - Fri Oct 23, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its third quarter financial results on Wednesday, Oct. 28, 2015, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
AMGN: 155.75 (+3.44)
Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:36PM CDT
Exelixis (EXEL) has started the process of a rolling submission of a new drug application to the FDA for Cometriq for the treatment of advanced kidney cancer.
AZN: 31.36 (+0.29), AMGN: 155.75 (+3.44), EXEL: 5.79 (+0.22)
eBay's (EBAY) 1st Earnings without PayPal: What's in Store? (revised)
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 1:03PM CDT
Our proven model shows that eBay is likely to beat earnings because it has the right combination of two key ingredients.
SKYW: 19.90 (+0.36), EBAY: 28.16 (+0.58), AMGN: 155.75 (+3.44), ANIK: 34.87 (+1.25)
Business events scheduled for the coming week
By The Associated Press - AP - Fri Oct 23, 12:43PM CDT
All times are Eastern.
RAI: 48.89 (+0.01), F: 15.67 (+0.09), QSR.TO: 49.17 (+0.57), ANTX: 47.28 (+0.16), PFE: 34.05 (+0.72), XOM: 82.98 (+0.09), AMGN: 155.75 (+3.44), CMCSK: 62.35 (+0.28), MO: 61.05 (-0.35), AET: 105.89 (+2.53), SBUX: 62.61 (+1.12), ANTM: 140.95 (+1.54), QSR: 37.33 (+0.33), GT: 32.97 (+0.40), WBA: 89.96 (+1.33), GILD: 107.99 (+0.39), MRK: 52.88 (+0.87), CVS: 103.95 (-0.34), TWTR: 30.28 (+1.13), CMCSA: 61.98 (+0.28), AAPL: 119.08 (+3.58), BABA: 75.62 (+4.63)
Relypsa's Hyperkalemia Drug Veltassa Approved in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 12:43PM CDT
Relypsa (RLYP) announced that its Veltassa was approved in the U.S. for the treatment of hyperkalemia.
ZSPH: 65.45 (+1.53), AZN: 31.36 (+0.29), RLYP: 13.80 (+2.04), AMGN: 155.75 (+3.44)
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Spectrum Pharmaceuticals' Evomela Gets CRL in the U.S.
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:12AM CDT
Spectrum (SPPI) announced that it has received a Complete Response Letter (CRL) from the FDA for Evomela.
AZN: 31.36 (+0.29), LGND: 89.30 (+2.20), AMGN: 155.75 (+3.44), SPPI: 5.33 (-1.31)
Foamix Starts Patient Enrollment in Phase II Study on FMX103
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:03AM CDT
Foamix (FOMX) announced the initiation of patient enrollment in a phase II study on FMX103 for the treatment of papulopustular rosacea.
AZN: 31.36 (+0.29), FOMX: 6.99 (+0.49), AMGN: 155.75 (+3.44), ANIK: 34.87 (+1.25)
Cat Allergy Pipeline Review, H2 2015 - 5 Companies & 2 Drug Profiles
M2 - Fri Oct 23, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sbgnrg/cat_allergy) has announced the addition of the "Cat Allergy - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cat Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cat Allergy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - ALK-Abello A/S - Amgen Inc. - Biomay AG - Circassia Pharmaceuticals Plc - Laboratorios LETI S.L. Drug Profiles - AMG-157 - BM-36 For more information visit http://www.researchandmarkets.com/research/sb...at_allergy
AMGN: 155.75 (+3.44)
Global Anal Cancer Pipeline Review, H2 2015 - 7 Companies & 8 Drug Profiles
M2 - Fri Oct 23, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5v4vqf/anal_cancer) has announced the addition of the "Anal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advaxis, Inc. - Amgen Inc. - Eli Lilly and Company - ISA Pharmaceuticals B.V. - MedImmune, LLC - Novartis AG - Sun Pharma Advanced Research Company Ltd. Drug Profiles - axalimogene filolisbac - Cell Therapy for HPV Associated Cancers - durvalumab tremelimumab - ISA-101 - paclitaxel albumin free - panitumumab - PDR-001 - prexasertib For more information visit http://www.researchandmarkets.com/research/5v...nal_cancer
ADXS: 10.77 (+0.47), AMGN: 155.75 (+3.44), LLY: 78.31 (+1.33), NVS: 92.98 (+0.55)
Battle Royale: Amgen Inc. vs. Biogen Inc.
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 23, 7:42AM CDT
Image source: Wikipedia.org . On the surface, Amgen and Biogen might not look like competitors. The two big biotechs don't go head-to-head with any of their major drugs. But there's one important way that Amgen and Biotech do battle against...
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44)
Amgen Receives CHMP Positive Opinion For IMLYGIC(TM) (Talimogene Laherparepvec)
PR Newswire - Fri Oct 23, 6:22AM CDT
Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending that IMLYGIC(TM) (talimogene laherparepvec) be granted approval for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. If approved by the European Commission, IMLYGIC would be the first in a class of novel agents known as oncolytic immunotherapies.
AMGN: 155.75 (+3.44)
Global Preventive Asthma Drugs Market 2015-2019
M2 - Fri Oct 23, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nsm45k/global_preventive) has announced the addition of the "Global Preventive Asthma Drugs Market 2015-2019" report to their offering. The global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019. The report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations. This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma: - Immunosuppressants - Leukotriene antagonists - Mast cell stabilizers - Corticosteroids - Combination of LABA/ ICS Key vendors - AstraZeneca - F. Hoffmann-La Roche - GlaxoSmithKline - Merck - Novartis Other prominent vendors - Abbott - Amgen - AptarGroup - Biotest - Boehringer Ingelheim - Chiesi Farmaceutici - Cytos - Dainippon Sumitomo - Medicinova - Mylan - Novartis - Orchid Chemicals and Pharmaceuticals - Pfizer - Rottapharm Madaus - Skyepharma - Sosei - Sunovion - Teva Pharmaceutical - Theravance - Vectura For more information visit http://www.researchandmarkets.com/research/ns...preventive
MRK: 52.88 (+0.87), AMGN: 155.75 (+3.44), GSK: 42.11 (+0.67), ATR: 71.40 (+0.11), NVS: 92.98 (+0.55)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Stock Market News for October 22, 2015
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 9:10AM CDT
Benchmarks ended Wednesday’s volatile trading session in the red following declines in healthcare and energy shares
KO: 42.79 (-0.45), KMI: 29.23 (-0.52), VRX: 116.16 (+6.29), MDT: 73.69 (+0.62), PFE: 34.05 (+0.72), UNH: 115.92 (+2.11), AMGN: 155.75 (+3.44), XOM: 82.98 (+0.09), COP: 54.61 (+0.03), BMY: 65.16 (+1.98), BA: 146.70 (+0.39), YHOO: 33.17 (+1.50), GM: 35.95 (+0.53), CVX: 91.24 (-0.38), OXY: 73.71 (-0.63)
Covered Call Alerts For Chipotle Mexican Grill, Horizon Pharma, Abbott Laboratories, Bank of America and Amgen Released By InvestorsObserver
PR Newswire - Thu Oct 22, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CMG, HZNP, ABT, BAC and AMGN.
ABT: 43.60 (+0.10), CMG: 649.72 (-0.90), HZNP: 17.06 (+3.94), AMGN: 155.75 (+3.44), BAC: 16.52 (+0.36)
The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 8:30AM CDT
The Zacks Analyst Blog Highlights: Altria, Nike, Apple, Amgen and Home Depot
HD: 124.61 (+0.25), NKE: 130.53 (-1.88), AMGN: 155.75 (+3.44), MO: 61.05 (-0.35), AAPL: 119.08 (+3.58)
Go Back to the Future with These 5 Market Crushing Stocks
Eric Dutram - Zacks Investment Research - Wed Oct 21, 3:55PM CDT
If you ever have a time machine that can go back to 1985, you better buy these top performing stocks which have crushed the market over the past 30 years.
HD: 124.61 (+0.25), NKE: 130.53 (-1.88), AMGN: 155.75 (+3.44), MO: 61.05 (-0.35), AAPL: 119.08 (+3.58)
